Stock Report

All about this stock under one free report Last Updated: 08-Oct-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Vertex Pharmaceuticals (VRTX) Key Ratios

Stock Card factsheet share-fund-plan-icon

$508.06

up-down-arrow $5.75 (1.14%)

As on 07-Oct-2026 13:39EDT

Market cap

info icon

$127,929 Mln

Revenue (TTM)

info icon

$12,624 Mln

P/E Ratio

info icon

29.5

P/B Ratio

info icon

6.5

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 11.62 12.45 10.56 9.92 13.56
EBIT 11.09 8.17 20.31 6.65 16.39
Net Profit 6.63 6.48 21.10 14.12 17.21
EPS 6.88 7.81 22.80 9.92 17.80
Book Value -- -- 15.70 10.89 17.16
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info 28.6534.1641.8338.562.55
Net Margin info --34.0834.89----
Return on equity info 14.1319.0022.6422.54-3.15
Return on Capital info 12.7717.32--19.42-2.93
Return on Assets info 10.5314.2414.8016.24-2.37
Debt to Equity (x) info ----0.000.210.11

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
--
19.42
-2.93
21.80
25.67
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

22.64

Higher than Peers by 62.39

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
22.64
22.54
-3.15
22.99
27.67
Peer Median
-39.75
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

14.80

Higher than Peers by 45.99

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
14.80
16.24
-2.37
17.71
21.04
Peer Median
-31.19
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

41.83

Higher than Peers by 118.36

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
41.83
38.56
2.55
44.83
48.01
Peer Median
-76.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

34.89

Higher than Peers by 120.46

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
34.89
32.74
-4.86
36.68
37.28
Peer Median
-85.56
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
--
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

10.56

Lower than Peers by 44.07

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
10.56
0.10
0.12
0.11
0.18
Peer Median
54.63
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

20.31

Higher than Peers by 21.70

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
20.31
1,560.07
-93.66
3.19
53.56
Peer Median
-1.39
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

21.10

Higher than Peers by 27.90

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
21.10
838.09
-114.80
8.96
41.84
Peer Median
-6.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

22.80

Higher than Peers by 8.66

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
22.80
8.51
-1.15
0.09
0.40
Peer Median
14.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

19.36

Higher than Peers by 28.86

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
19.36
--
--
--
--
Peer Median
-9.50
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
--
0.21
0.11
0.05
0.06
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
--
0.00
0.01
0.00
0.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

3.19

Lower than Peers by 2.65

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
3.19
2.90
2.69
3.99
4.83
Peer Median
5.84
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

2.74

Lower than Peers by 2.96

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
2.74
2.46
2.35
3.78
4.66
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

800.23

Higher than Peers by 802.37

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
800.23
350.11
9.17
100.32
78.23
Peer Median
-2.15
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

16.91

Lower than Peers by 2.15

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
16.91
17.00
14.60
15.84
16.15
Peer Median
19.05
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.42

Higher than Peers by 0.36

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
0.42
0.50
0.49
0.48
0.57
Peer Median
0.07
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
--
55.39
52.58
55.62
52.74
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
--
292.28
231.99
173.54
137.56
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
--
88.40
92.82
96.77
84.34
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
--
259.28
191.75
132.39
105.96
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

29.50

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
29.50
29.37
-195.86
29.33
22.63
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

6.46

Higher than Peers by 1.99

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
6.46
6.22
6.39
6.04
5.40
Peer Median
4.48
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

24.51

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
24.51
23.31
206.74
20.79
14.72
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

127,929

Higher than Peers by 127,788

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Vertex Pharmaceuticals (VRTX)
127,929
--
--
--
--
Peer Median
142
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...